Kolon TissueGene, Inc. (KOSDAQ: A950160)
Health Care · Biotechnology · US
₩20,750.00
-27.32% today · -43.5% 1Y
Kolon TissueGene, Inc. (KOSDAQ: A950160) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.27B.
Over the last twelve months the share price has lost 43.5%, trading between 11.47K and 149.00K.
Tweenvest scores Kolon TissueGene, Inc. across four factors: quality 29/100, value 37/100, growth 63/100. Its strongest factor is growth.
A950160 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.27B
- Revenue (TTM)
- $3.47M
- P/E
- —
- EPS
- -3,456.66
- Dividend yield
- —
- Beta (5Y)
- -0.38
- 52-week high
- ₩149,000.00
- 52-week low
- ₩11,470.00
- Avg volume (3M)
- —
- Shares outstanding
- 84.97M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.